Have multiple conditions? Click here

New Clinical Trials for Alzheimer Disease

Since 2010 there have been more than 850 clinical trials for Alzheimer disease. There are over 400 pharmaceuticals that are currently being tested for treating Alzheimer disease. About one quarter of these are in Phase III studies, meaning the next step is approval for use in patients by a government agency. Some of the clinical research focuses on the development of cures for patients who have already been diagnosed while others are more interested in finding ways to prevent Alzheimer disease.
 
If you have been diagnosed with this difficult disease or are the caregiver of an Alzheimer sufferer, please review the list of current Alzheimer disease clinical trials. If you qualify you can participate at no cost to you. 
 

What is Alzheimer Disease?

Alzheimer disease is the most common form of dementia. It is also known as senile dementia of the Alzheimer type or primary degenerative dementia of the Alzheimer’s type. There is currently no cure for Alzheimer disease. Alzheimer disease develops in stages and is most often seen in people over 65 years of age. Early stages include difficulty with memory and things that may initially be attributed to old age. As the disease progresses the patient suffers from increasing memory loss, confusion, aggression, and language problems. In late stages the patient requires constant care.
 

Alzheimer Disease Treatments

The cause of Alzheimer disease is unclear except that it involves plaques and tangles in the brain. Because of the cause being unclear treating Alzheimer disease has proven difficult. There is no known way of slowing down the progression of the disease. Pharmaceuticals, behavioral changes and care-giving are current methods used in the treatment of Alzheimer Disease. Some success has been seen in lifestyle changes such as increased mental stimulation, exercise and good diet.

Have multiple conditions? Click here

Showing 1-100 of 610
There are 610 Alzheimer Disease Clinical Trials
Name City State Zip
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Tuscaloosa AL 35404
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease Birmingham AL 35294
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease Birmingham AL 35294
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) Birmingham AL 35233
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Birmingham AL 35233
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Birmingham AL 35233
Alzheimer's Disease Neuroimaging Initiative 2 Birmingham AL 35294
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease Tucson AZ 85721
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Tucson AZ 85724
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Tucson AZ 86741
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease Tucson AZ 85741
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease Scottsdale AZ 85259
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease Scottsdale AZ 85259
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease Phoenix AZ 85006
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease Phoenix AZ 85351
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease Phoenix AZ 85351
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Phoenix AZ 85006
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Phoenix AZ 85351
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Phoenix AZ 85004
To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden Phoenix AZ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease Phoenix AZ 85050
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Phoenix AZ 85006
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Phoenix AZ 85351
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease Phoenix AZ 85351
Alzheimer's Disease Neuroimaging Initiative 2 Phoenix AZ 85006
Alzheimer's Disease Neuroimaging Initiative 2 Phoenix AZ 85351
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Peoria AZ 85381
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease. Peoria AZ
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology Peoria AZ
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Gilbert AZ 85234
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease. Little Rock AR
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease Fayetteville AR 72703
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Conway AR 72034
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Torrance CA 90502
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Temecula CA 92591
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Stanford CA 94305
Alzheimer's Disease Neuroimaging Initiative 2 Stanford CA 94305
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease Santa Rosa CA 95405
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease Santa Clara CA 95051
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease. Santa Clara CA 95051
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology Santa Clara CA 95051
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study Santa Clara CA 95051
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Santa Ana CA 92701
Side Effects of Newer Antipsychotics in Older Adults San Francisco CA 94110
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease San Francisco CA 94115
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease San Francisco CA 94143
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease San Francisco CA 94110
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease San Francisco CA 94143
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type San Francisco CA
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity San Francisco CA 94110
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity San Francisco CA 94115
Alzheimer's Disease Neuroimaging Initiative 2 San Francisco CA 94110
Alzheimer's Disease Neuroimaging Initiative 2 San Francisco CA 94115
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease San Fernando Valley CA 91403
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type San Fernando Valley CA 91403
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease San Diego CA 92103
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease San Diego CA 92108
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type San Bernardino CA 92374
Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil Redlands CA 92374
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Poway CA 92064
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Orange CA 92868
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Orange CA 92868
Alzheimer's Disease Neuroimaging Initiative 2 Orange CA 92868
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Oceanside CA 92056
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Newport Beach CA 92660
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease National City CA 91950
Amyloid Plaque and Tangle Imaging in Aging and Dementia Los Angeles CA 90024
Online Caregiver Psychoeducation and Support for Alzheimer's Los Angeles CA 90073
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease Los Angeles CA 90033
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease Los Angeles CA 90095
Dominantly Inherited Alzheimer Network (DIAN) Los Angeles CA 90033
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease Los Angeles CA 90033
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Los Angeles CA 90095
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease Los Angeles CA 90073
Citalopram for Agitation in Alzheimer's Disease Los Angeles CA 90033
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab Los Angeles CA 90073
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Los Angeles CA 90033
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease Los Angeles CA 90073
Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome Los Angeles CA 90095
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia Los Angeles CA 90095
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers Los Angeles CA 90073
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease Los Angeles CA 90095
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Los Angeles CA 90033
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Los Angeles CA 90033
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Los Angeles CA 90095
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease Los Angeles CA 90073
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease Los Angeles CA 90095
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease Los Angeles CA 90095
Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls Los Angeles CA 90095
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease Los Angeles CA 90073
Alzheimer's Disease Neuroimaging Initiative 2 Los Angeles CA 90033
Alzheimer's Disease Neuroimaging Initiative 2 Los Angeles CA 90024
Alzheimer's Disease Neuroimaging Initiative 2 Los Angeles CA 90033
Alzheimer's Disease Neuroimaging Initiative 2 Los Angeles CA 90095
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease Long Beach CA 90822
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease Long Beach CA 90806
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease Long Beach CA 90806
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease Long Beach CA 90806
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type La Habra CA 90631
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity Irvine CA 92868

Showing 1-100 of 610
Alabama - Alaska - Arizona - Arkansas - California - Colorado - Connecticut - Delaware - Washington DC - Florida - Georgia - Hawaii - Idaho - Illinois - Indiana - Iowa - Kansas - Kentucky - Louisiana - Maine - Maryland - Massachusetts - Michigan - Minnesota - Mississippi - Missouri - Montana - Nebraska - Nevada - New Hampshire - New Jersey - New Mexico - New York - North Carolina - North Dakota - Ohio - Oklahoma - Oregon - Pennsylvania - Rhode Island - South Carolina - South Dakota - Tennessee - Texas - Utah - Vermont - Virginia - Washington - West Virginia - Wisconsin - Wyoming
For Sponsors: Promote Your Study | For Research Sites: Promote Your Site

Copyright 2012 Clinical Trials Institute, LLC | All Rights Reserved
Login
Forgot password?
Enter your email and we will resend your password
Register